Lexington High School’s student newspaper launched a science series Sept. 30, exploring how developments in research connect with students’ classroom learning and future lives.
Written by Jiawei Liu, the first “Science and Us” installment in The Musket examines personalized cancer treatment. The series plans to address medicine, biotechnology, artificial intelligence and robotics through interviews with students and teachers.
Biology teacher Jocelyn Sheahan explained how genetics and immune-system lessons help students understand the research. Sophomores Nathan Xu and Aleks Mishchenko initially associated cancer vaccines with shots that prevent disease.
The treatment discussed in the article serves a different purpose.
Experimental treatment aims to reduce recurrence
Moderna and Merck are developing intismeran autogene, an individualized mRNA therapy based on mutations identified in each patient’s tumor. It carries instructions for up to 34 tumor-associated targets, intended to help the immune system recognize cancer cells, according to Merck’s description.
On Aug. 19, the companies announced positive interim Phase 3 results from a trial involving 1,137 patients with high-risk melanoma that had been surgically removed.
The combination of intismeran and Keytruda improved recurrence-free survival and distant metastasis-free survival compared with Keytruda alone, the companies said. Follow-up continues, including evaluation of overall survival.
Separately, five-year follow-up from an earlier Phase 2b study showed a 49% relative reduction in the risk of recurrence or death with the combination, according to results presented at ASCO in 2026.
Students consider cost and access
The Musket’s interviewees expressed different expectations about how quickly personalized medicine might become widespread, but all questioned its affordability.
Xu welcomed the connection between biology coursework and medical research. Mishchenko expressed caution about newer technology and the expense of producing individual treatments.
Sheahan encouraged students considering scientific careers to develop analytical skills, read research papers and practice explaining technical ideas clearly.
Intismeran remains investigational. In their August announcement, Moderna and Merck said they planned to present the Phase 3 data at a medical meeting and discuss regulatory submissions.
